ALNY SEC Filings
SEC filings for ALNY. Annual and quarterly reports, 8-K events, Form 4 insider filings and 13D/G stake disclosures.
| Form | Filed | Accession |
|---|---|---|
| 10-QAIAlnylam reports very strong growth, driven by AMVUTTRA in ATTR-CM: revenue up 67% for the quarter, a swing to net income, and a confident Alnylam 2030 strategy. | Jul 30, 2026 | 0001178670-26-000062EDGAR |
| 10-QAIAlnylam reports a transformational quarter with revenue up 96% and a swing to $206M net income, alongside an ambitious Alnylam 2030 strategy. | Apr 30, 2026 | 0001628280-26-028605EDGAR |
| 10-QAIAlnylam's MD&A is markedly positive, reflecting a swing to profitability, 149% quarterly revenue growth, and multiple product approvals and clinical milestones. | Oct 30, 2025 | 0001628280-25-047345EDGAR |
SEC filings for companies related to ALNY
Never miss a ALNY filing.
Get an email when ALNY files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.